Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-06-23: Reporting owner Walsh Dennis Leo; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-23: Reporting owner Bristol James Arthur; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-23: Reporting owner Squarer Ron; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-23: Reporting owner Martin John Richard; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-06-23 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-06-23 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,500 18,500 owned after | $13.98 exercise price | 2022-06-24 | |
| 2022-01-18 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,000 82,000 owned after | $8.27 exercise price | 2022-01-20 | |
| 2022-01-18 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,570 9,570 owned after | $5.22 | 2022-01-20 | |
| 2022-01-18 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +54,667 54,667 owned after | $8.27 exercise price | 2022-01-20 | |
| 2022-01-18 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,000 82,000 owned after | $8.27 exercise price | 2022-01-20 | |
| 2022-01-18 | Pitman Jama Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +54,667 54,667 owned after | $8.27 exercise price | 2022-01-20 | |
| 2022-01-18 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,000 82,000 owned after | $8.27 exercise price | 2022-01-20 | |
| 2022-01-18 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −415,000 415,000 owned after | $8.27 exercise price | 2022-01-20 |